Logo
x

Search category

Subscribe Now

hutchmed

The NMPA Accepts HUTCHMED and Innovent’s NDA for Fruquintinib Plus Sintilimab with Priority Review to Treat Endometrial Cancer

The NMPA Accepts HUTCHMED and Innovent’s NDA for Fruquintinib Plus Sintilimab with Priority Review to Treat Endometrial Cancer

  • April 2, 2024
HUTCHMED Reports the NMPA’s Acceptance of sNDA for Savolitinib to Treat NSCLC

HUTCHMED Reports the NMPA’s Acceptance of sNDA for Savolitinib to Treat NSCLC

  • March 28, 2024
HUTCHMED Receives the Pharmacy and Poisons Board of Hong Kong’s Approval for Elunate (fruquintinib) to Treat Metastatic Colorectal Cancer (CRC)

HUTCHMED Receives the Pharmacy and Poisons Board of Hong Kong’s Approval for Elunate (fruquintinib) to Treat Metastatic Colorectal...

  • January 30, 2024
HUTCHMED Reports NDA Acceptance with Priority Review by the US FDA for Sovleplenib to Treat Primary Immune Thrombocytopenia (PIT)

HUTCHMED Reports NDA Acceptance with Priority Review by the US FDA for Sovleplenib to Treat Primary Immune Thrombocytopenia (PIT)

  • January 11, 2024
Hutchmed Completes Enrollment for the P-II/III Trial for Fruquintinib + Sintilimab to Treat Renal Cell Carcinoma in China

Hutchmed Completes Enrollment for the P-II/III Trial for Fruquintinib + Sintilimab to Treat Renal Cell Carcinoma in China

  • December 13, 2023
HUTCHMED Reports the NDA Submission of Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

HUTCHMED Reports the NDA Submission of Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

  • September 29, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.